Sotera Health Company $SHC Stock Holdings Increased by T. Rowe Price Investment Management Inc.

Key Points

• T. Rowe Price Investment Management Inc. increased its stake in Sotera Health Company by 5.9%, owning 8,045,502 shares valued at approximately $93.81 million.
• Sotera Health reported a quarterly earnings per share of $0.20, surpassing analysts' estimates, with a revenue of $294.34 million which was also above expectations.
• Several analysts have recently upgraded their ratings for Sotera Health, with Goldman Sachs raising its target price from $14.00 to $17.00 and maintaining a "buy" rating.

T. Rowe Price Investment Management Inc. raised its holdings in shares of Sotera Health Company (NASDAQ:SHC - Free Report) by 5.9% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 8,045,502 shares of the company's stock after purchasing an additional 450,761 shares during the period. T. Rowe Price Investment Management Inc. owned approximately 2.83% of Sotera Health worth $93,811,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of SHC. Sculptor Capital LP bought a new stake in Sotera Health during the fourth quarter valued at about $68,400,000. Two Seas Capital LP increased its holdings in shares of Sotera Health by 624.0% in the fourth quarter. Two Seas Capital LP now owns 2,896,136 shares of the company's stock worth $39,619,000 after purchasing an additional 2,496,136 shares during the last quarter. D. E. Shaw & Co. Inc. increased its holdings in shares of Sotera Health by 140.8% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 2,624,750 shares of the company's stock worth $35,907,000 after purchasing an additional 1,534,666 shares during the last quarter. Ananym Capital Management LP bought a new stake in shares of Sotera Health in the fourth quarter worth about $13,680,000. Finally, Dimensional Fund Advisors LP increased its holdings in shares of Sotera Health by 27.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 3,143,955 shares of the company's stock worth $43,004,000 after purchasing an additional 673,979 shares during the last quarter. 91.03% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Sotera Health

In related news, insider Michael P. Rutz sold 126,611 shares of Sotera Health stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $16.38, for a total transaction of $2,073,888.18. Following the sale, the insider owned 450,204 shares of the company's stock, valued at $7,374,341.52. The trade was a 21.95% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 55.12% of the stock is owned by company insiders.

Sotera Health Stock Performance

NASDAQ SHC traded down $0.06 during trading hours on Wednesday, hitting $16.34. 214,602 shares of the stock were exchanged, compared to its average volume of 1,238,333. Sotera Health Company has a 12-month low of $9.53 and a 12-month high of $17.08. The company has a quick ratio of 2.23, a current ratio of 2.47 and a debt-to-equity ratio of 4.49. The company has a market cap of $4.64 billion, a price-to-earnings ratio of 203.71 and a beta of 1.81. The stock has a 50-day moving average of $12.56 and a 200 day moving average of $12.20.

Sotera Health (NASDAQ:SHC - Get Free Report) last released its quarterly earnings results on Friday, August 8th. The company reported $0.20 EPS for the quarter, beating the consensus estimate of $0.17 by $0.03. Sotera Health had a net margin of 2.14% and a return on equity of 39.42%. The business had revenue of $294.34 million for the quarter, compared to analyst estimates of $275.81 million. During the same period in the prior year, the business earned $0.19 earnings per share. The company's quarterly revenue was up 6.4% on a year-over-year basis. Sotera Health has set its FY 2025 guidance at 0.750-0.820 EPS. As a group, equities research analysts forecast that Sotera Health Company will post 0.61 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have weighed in on SHC shares. Wall Street Zen upgraded Sotera Health from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 16th. Barclays reissued an "overweight" rating on shares of Sotera Health in a research report on Friday, August 8th. Finally, The Goldman Sachs Group raised shares of Sotera Health from a "neutral" rating to a "buy" rating and increased their target price for the stock from $14.00 to $17.00 in a research note on Monday, May 5th. Four equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. Based on data from MarketBeat, Sotera Health has a consensus rating of "Moderate Buy" and an average price target of $16.00.

Sotera Health Company Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.